Elk Creek Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Elk Creek Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,866	Closed	-$252K	–	135
2019 Q1	$252K	Sell	1,866 -770	-29%	-$95.7K	0.02%	127
2018 Q4	$257K	Sell	2,636 -1,943	-42%	-$230K	0.02%	127
2018 Q3	$637K	Hold	4,579	–	–	0.03%	128
2018 Q2	$568K	Sell	4,579 -64	-1%	-$7.48K	0.03%	130
2018 Q1	$518K	Buy	4,643 +800	+21%	+$95.6K	0.03%	136
2017 Q4	$460K	Buy	3,843 +54	+1%	+$6.58K	0.03%	137
2017 Q3	$532K	Buy	3,789 +92	+2%	+$12.5K	0.03%	132
2017 Q2	$450K	Buy	3,697 +1,061	+40%	+$123K	0.03%	131
2017 Q1	$320K	Buy	+2,636	New	+$340K	0.02%	142
2015 Q2	–	Sell	-3,780	Closed	-$655K	–	170
2015 Q1	$655K	Sell	3,780 -743	-16%	-$134K	0.07%	159
2014 Q4	$837K	Buy	+4,523	New	+$838K	0.11%	149

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Elk Creek Partners's ALXN Position: Q2 2019 in Review

Elk Creek Partners sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 1,866 shares — an estimated $252K sold.

Elk Creek Partners first reported a position in ALXN in Q4 2014 and held it in 11 quarters. The position peaked at $837K in Q4 2014. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

Elk Creek Partners reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Elk Creek Partners sold 1,866 Alexion Pharmaceuticals shares in Q2 2019, an estimated $252K.
Elk Creek Partners first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 11 quarters.
Elk Creek Partners's Alexion Pharmaceuticals position peaked at $837K in Q4 2014.
636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Elk Creek Partners's 13F filing for Q2 2019, filed 9 Aug 2019.